ProCE Banner Activity

Liraglutide in Diabetes: Cardiovascular Implications of the LEADER Trial

Clinical Thought
Join Vivian A. Fonesca, MD, FRCP, as he shares his thoughts on the results of the phase III LEADER trial, which demonstrated a cardiovascular benefit for liraglutide in patients with type 2 diabetes who have cardiovascular disease.

Released: August 15, 2016

Expiration: August 14, 2017

No longer available for credit.


Provided by

Provided by the Endocrine Society, in collaboration with Clinical Care Options.
ProCE Banner


Supported by educational grants from

Merck Human Health HIV

Novo Nordisk Inc